BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 30555034)

  • 21. Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis.
    Wan Z; Han B
    Front Oncol; 2020; 10():579221. PubMed ID: 33117717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
    Patnaik MM; Lasho TL
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):450-459. PubMed ID: 33275756
    [TBL] [Abstract][Full Text] [Related]  

  • 23. I walk the other line: myelodysplastic/myeloproliferative neoplasm overlap syndromes.
    Gerds AT
    Curr Hematol Malig Rep; 2014 Dec; 9(4):400-6. PubMed ID: 25195196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.
    Moyo TK; Mendler JH; Itzykson R; Kishtagari A; Solary E; Seegmiller AC; Gerds AT; Ayers GD; Dezern AE; Nazha A; Valent P; van de Loosdrecht AA; Onida F; Pleyer L; Cirici BX; Tibes R; Geissler K; Komrokji RS; Zhang J; Germing U; Steensma DP; Wiseman DH; Pfeilstöecker M; Elena C; Cross NCP; Kiladjian JJ; Luebbert M; Mesa RA; Montalban-Bravo G; Sanz GF; Platzbecker U; Patnaik MM; Padron E; Santini V; Fenaux P; Savona MR;
    BMC Cancer; 2022 Sep; 22(1):1013. PubMed ID: 36153475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myelodysplastic and myeloproliferative neoplasms: updates on the overlap syndromes.
    Thota S; Gerds AT
    Leuk Lymphoma; 2018 Apr; 59(4):803-812. PubMed ID: 28771058
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in myelodysplastic/myeloproliferative neoplasms.
    Prakash S; Arber DA; Bueso-Ramos C; Hasserjian RP; Orazi A
    Virchows Arch; 2023 Jan; 482(1):69-83. PubMed ID: 36469102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Revisiting diagnostic criteria for myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Borderline cases without anemia exist.
    Li P; Shahmarvand N; Lynch D; Gotlib JR; Merker JD; Zehnder JL; George TI; Ohgami RS
    Int J Lab Hematol; 2019 Jun; 41(3):345-352. PubMed ID: 30811101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms.
    Gerke MB; Christodoulou I; Karantanos T
    Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms.
    Palomo L; Meggendorfer M; Hutter S; Twardziok S; Ademà V; Fuhrmann I; Fuster-Tormo F; Xicoy B; Zamora L; Acha P; Kerr CM; Kern W; Maciejewski JP; Solé F; Haferlach C; Haferlach T
    Blood; 2020 Oct; 136(16):1851-1862. PubMed ID: 32573691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical analysis and literature review of a case with the myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
    Long B; Shi H; Zhu C
    Hematology; 2020 Dec; 25(1):283-285. PubMed ID: 32657243
    [No Abstract]   [Full Text] [Related]  

  • 32. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features.
    Orazi A; Germing U
    Leukemia; 2008 Jul; 22(7):1308-19. PubMed ID: 18480833
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group.
    Kanagal-Shamanna R; Orazi A; Hasserjian RP; Arber DA; Reichard K; Hsi ED; Bagg A; Rogers HJ; Geyer J; Darbaniyan F; Do KA; Devins KM; Pozdnyakova O; George TI; Cin PD; Greipp PT; Routbort MJ; Patel K; Garcia-Manero G; Verstovsek S; Medeiros LJ; Wang SA; Bueso-Ramos C
    Mod Pathol; 2022 Apr; 35(4):470-479. PubMed ID: 34775472
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.
    Patnaik MM; Lasho T
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):460-464. PubMed ID: 33275673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN with RS-T) complicated by hyperleukocytosis and gene analysis in relation to leukocytosis.
    Aoyama Y; Sakai K; Kodaka T; Tsunemine H; Nishio K; Itoh T; Inoue D; Takahashi T
    J Clin Exp Hematop; 2019 Mar; 59(1):29-33. PubMed ID: 30726782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genomics of myelodysplastic/myeloproliferative neoplasm.
    Patwardhan PP; Aarabi M; Aggarwal N
    Semin Diagn Pathol; 2023 May; 40(3):195-201. PubMed ID: 37105794
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myelodysplastic/myeloproliferative neoplasms.
    Cazzola M; Malcovati L; Invernizzi R
    Hematology Am Soc Hematol Educ Program; 2011; 2011():264-72. PubMed ID: 22160044
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical characteristics of Japanese patients with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
    Edahiro Y; Ochiai T; Hashimoto Y; Morishita S; Shirane S; Inano T; Furuya C; Koike M; Noguchi M; Usuki K; Shiratsuchi M; Nakajima K; Ohtsuka E; Tanaka H; Kawata E; Nakamae M; Ueda Y; Aota Y; Sugita Y; Ohara S; Yamasaki S; Asagoe K; Yoshida S; Yamanouchi J; Suzuki S; Kondo T; Kanisawa Y; Toyama K; Omura H; Mizuchi D; Sakamaki S; Ando M; Komatsu N
    Int J Hematol; 2023 Jul; 118(1):47-53. PubMed ID: 37058247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Many faces of SF3B1-mutated myeloid neoplasms: concurrent mutational profiles contribute to the diverse clinical and morphologic features.
    Aqil B; Sukhanova M; Behdad A; Jennings L; Lu X; Chen Q; Chen YH; Gao J
    Hum Pathol; 2022 Nov; 129():81-89. PubMed ID: 36087739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
    Wang SA; Hasserjian RP; Fox PS; Rogers HJ; Geyer JT; Chabot-Richards D; Weinzierl E; Hatem J; Jaso J; Kanagal-Shamanna R; Stingo FC; Patel KP; Mehrotra M; Bueso-Ramos C; Young KH; Dinardo CD; Verstovsek S; Tiu RV; Bagg A; Hsi ED; Arber DA; Foucar K; Luthra R; Orazi A
    Blood; 2014 Apr; 123(17):2645-51. PubMed ID: 24627528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.